
“An experimental drug combination cured 70 percent of patients with hepatitis C in early trials, offering hope of a simpler remedy for the chronic liver disease, US researchers said Tuesday. The phase II trial described in the Journal of the American Medical Association (JAMA) studied the effectiveness and safety of an experimental drug, sofosbuvir, taken with the licensed antiviral drug ribavirin. The drugs were administered orally, an improvement over the current treatment which involves weekly injections with interferon-alpha and can cause depression, flu-like symptoms and anemia. All nine who completed the regimen had no virus detectable 24 weeks after therapy ended.”
Related posts:
Snowden Gets Whistleblower Award in Germany
Obama recognizes Syrian rebels as ‘legitimate representative’ of the people
Kenya’s new cellphone money model could disrupt global banking industry
Police chopper, riot squad meet lone anti-Islam cartoon protestor
Paris tax hunt sends French to Switzerland
Woman scams metal buyers out of thousands with fake silver bars
Russia Urges Companies to Delist Abroad Amid Sanctions
Indiana man argues his constitutional right to flip off police
Road is built around a house after elderly Chinese couple refuse to move
Amazon asks for laxer online shopping rules in India
Lead investigator in Oscar Pistorius case is himself facing attempted murder charges
A Long-Distance Relationship With the I.R.S.
Mexican journalist acquitted of drug charges pens book on hellish prison experience
Halliburton pleads guilty to destroying Gulf spill evidence
NYC Woolworth Tower Condo Priced at Record $110 Million